Pharmaceutical and healthcare company Hutchison China MediTech, which counts Mitsui as an investor, priced its American depositary shares at $13.50 each.

The Novo and Roche-backed company, which has raised $108m in venture funding, is set to price 4.7 million shares at between $15 and $17.

Intel Capital, an investor since 2011, achieved an exit in a Chinese IPO, and has now exited a quarter of its 120 China-based portfolio companies.

Eye-tracking component maker Tobii has gone public in a $46m initial public offering, roughly three years after Intel paid $21m for a 10% stake.

The cancer treatment developer raised $52.8m, floating beneath its $14 to $16 range, as existing backer Fidelity invested $8m.

The gene therapy developer, backed by Roche Venture Fund, floated in the middle of its range after raising more than $80m in venture funding.

The company, backed by Novartis, Sanofi and Elan Science One, priced its initial public offering below its target range at $8 per share.

The China-based immuno-oncology company, backed by Merck & Co since 2011, floated at the top of it range and has gained since its debut yesterday.

Genome editing company Editas, backed by Alphabet and Partners Healthcare, has secured $94.4m, pricing the initial public offering at the bottom of the $16 to $18 range.